Celltrion announces positive top-line results from global Phase III trial of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment

Must Read

infected animals was confirmed with a clinical dosage of regdanvimab (CT-P59)1
Incheon, South Korea–(Antara/Business Wire.

Latest News

RI calls affordable women’s basic needs as policy consideration

Jakarta (ANTARA) - Minister of Women’s Empowerment and Child Protection Arifah Fauzi said the ministry is committed to ensuring...

More Articles Like This